Insilico Medicine (03696) announced that it has entered into a strategic drug research and development collaboration with Qilu Pharmaceutical Group and its subsidiary, Shanghai Qilu Pharmaceutical Research Center, signing a related agreement. Through this partnership, the two parties will leverage Insilico's proprietary Pharma.AI solution to jointly develop small molecule inhibitors for specific targets, focusing on the management of cardiovascular and metabolic diseases. Under the terms of the agreement, Insilico will utilize its independently built Pharma.AI platform to concentrate on the design and optimization of novel small molecule drugs for the metabolic disease area, while Qilu Pharmaceutical will be responsible for subsequent development and commercialization activities. The total value of the agreement exceeds HKD 931 million, comprising development and sales milestone payments, as well as a single-digit tiered royalty on future net sales.